{"disease":{"id":"thyroid-carcinoma","name":"thyroid carcinoma"},"drugs":{"marketed":[{"drug_id":"cabometyx","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"Cabometyx","company_name":"Exelixis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2200","mechanism":"Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis."},{"drug_id":"lenvatinib","indication_name":"Follicular thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"lenvatinib","indication_name":"Papillary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"selpercatinib","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retevmo","generic_name":"SELPERCATINIB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":69,"revenue":"700","mechanism":"Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"cinacalcet","indication_name":"Parathyroid Carcinoma with Hypercalcemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sensipar","generic_name":"CINACALCET","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"Calcium-sensing Receptor Agonist","quality_score":65,"revenue":null,"mechanism":"Sensipar works by activating the calcium-sensing receptor, which helps regulate calcium levels in the blood."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"zactima","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zactima","company_name":"Barbara Ann Karmanos Cancer Institute","drug_phase":"discontinued","molecular_target":"AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"cabozantinib","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"CABOZANTINIB","company_name":"Exelixis Inc","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":53,"revenue":null,"mechanism":"Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis."},{"drug_id":"tumor-tissue","indication_name":"Anaplastic Thyroid Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pralsetinib","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gavreto","generic_name":"PRALSETINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"RET","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Pralsetinib inhibits RET kinase and its oncogenic fusions/mutations, blocking downstream signaling and reducing tumor growth."},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Thyroid Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"caprelsa","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Caprelsa","company_name":"Genzyme, a Sanofi Company","drug_phase":"marketed","molecular_target":"AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"sodium-iodide-i-131","indication_name":"Thyroid Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM IODIDE I 131","company_name":"","drug_phase":"marketed","molecular_target":"sodium-iodide symporter (NIS), thyroid peroxidase","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Iodide is transported and concentrated in thyroid cells, oxidized to iodinium, and used to iodinate thyroglobulin, with I-131's beta emission causing the therapeutic effect."},{"drug_id":"vandetanib","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caprelsa","generic_name":"VANDETANIB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Receptor-interacting serine/threonine-protein kinase 2","drug_class":"Kinase Inhibitor [EPC]","quality_score":64,"revenue":null,"mechanism":"Caprelsa works by blocking a specific protein that helps cancer cells grow and spread."},{"drug_id":"evocalcet","indication_name":"Hypercalcemia in parathyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orkedia","generic_name":"EVOCALCET","company_name":"Kyowa Hakko Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"","quality_score":27,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05178186","title":"Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":22974,"lead_sponsor_name":"University of Cagliari","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT06779747","title":"Evaluation of Different Diagnostic Therapeutic Strategies in Patients with Thyroid Pathology","phase":"","overall_status":"RECRUITING","enrollment_count":5850,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06871956","title":"PMRA and Shapley-Based Machine Learning for Predicting Lymph Node Metastasis in Central Subregions of Clinically Node-Negative Papillary Thyroid Microcarcinoma: a Prospective Multicenter Validation and Development of a Web Calculator","phase":"","overall_status":"COMPLETED","enrollment_count":4882,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT03382158","title":"International PPB/DICER1 Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3400,"lead_sponsor_name":"Children's Hospitals and Clinics of Minnesota","has_results":false},{"nct_id":"NCT07299318","title":"Multimodal Deep Learning for Lymph Node Metastasis in Thyroid Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3200,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06592118","title":"Clinical and Surgical Outcomes of Thyroid Carcinoma in Children and Adolescents","phase":"","overall_status":"COMPLETED","enrollment_count":3068,"lead_sponsor_name":"Dezhou Hospital Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT07473518","title":"Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":2550,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT04216732","title":"Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management","phase":"","overall_status":"RECRUITING","enrollment_count":2030,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06725628","title":"Multiomics Study of Biological Behavior of Lymph Node Metastasis in Papillary Thyroid Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Tianhan Zhou","has_results":false},{"nct_id":"NCT06583057","title":"Multicenter Comparison of Thermal Ablation Versus Thyroid Lobectomy for Subcapsular Papillary Thyroid Microcarcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT07249125","title":"Safety and Quality of Life of Three Treatment Strategies for Low-Risk Papillary Thyroid Microcarcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1630,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06399159","title":"Prediction of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma Based on Ultrasound and Cytological Images","phase":"","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Nanchong Central Hospital","has_results":false},{"nct_id":"NCT05229341","title":"Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules","phase":"NA","overall_status":"RECRUITING","enrollment_count":1450,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04666103","title":"Function Integrity of Neck Anatomy in Thyroid Surgery","phase":"NA","overall_status":"RECRUITING","enrollment_count":1264,"lead_sponsor_name":"Wuhan University","has_results":false},{"nct_id":"NCT07359586","title":"Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT05191927","title":"A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04197960","title":"Microwave Ablation and Surgical Resection for Micropapillary Thyroid Carcinoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":973,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT06623578","title":"Comparative Study of Transaxillary Robotic Thyroidectomy With MRND Versus Conventional Open Surgery in N1b PTC","phase":"NA","overall_status":"RECRUITING","enrollment_count":876,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06146764","title":"CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07042984","title":"RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":800,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT06931743","title":"The Application of Electrical Stimulation in Postoperative Pain Management of Thyroid Surgery","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":668,"lead_sponsor_name":"Xiaonan Huang","has_results":false},{"nct_id":"NCT06207188","title":"Identification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters","phase":"","overall_status":"RECRUITING","enrollment_count":650,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06626581","title":"Iodine Status and Characteristics of Papillary Thyroid Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Shandong Provincial Hospital","has_results":false},{"nct_id":"NCT05962892","title":"A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT07357571","title":"Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06971965","title":"Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":578,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT04593277","title":"Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":549,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03942380","title":"Cell-free Tumor DNA in Head and Neck Cancer Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Christian von Buchwald","has_results":false},{"nct_id":"NCT06261190","title":"Active Surveillance for Low-risk Papillary Thyroid Carcinoma","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":499,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT07054229","title":"Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study","phase":"","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT02185560","title":"Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":453,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04624477","title":"Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06852144","title":"PET-TC in Thyroid Evaluation","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":418,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03776123","title":"Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients","phase":"","overall_status":"COMPLETED","enrollment_count":347,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT03012620","title":"Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":334,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT03510143","title":"Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery","phase":"NA","overall_status":"UNKNOWN","enrollment_count":330,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT00880503","title":"Collection of Tissue Samples for Study of Multidrug Resistance","phase":"","overall_status":"COMPLETED","enrollment_count":325,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06439745","title":"More Than 50% of Unifocal cN0 T1b/Small T2 Papillary Thyroid Carcinoma May Require Completion Thyroidectomy if Nodal Status is Evaluated","phase":"","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT03039439","title":"Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06730893","title":"Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":310,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT04500925","title":"The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience","phase":"","overall_status":"COMPLETED","enrollment_count":301,"lead_sponsor_name":"Tel-Aviv Sourasky Medical Center","has_results":false},{"nct_id":"NCT05932121","title":"Cross-sectional Case and Control Study on Quality of Life, Appearance and Functions in PTC Via Different Surgical Approach","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}